Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463120 | 0.88 | MMP2 (0.64) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL4622957 | 0.88 | MMP2 (0.64) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL4622948 | 0.88 | MMP2 (0.64) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL6522414 | 0.84 | MMP2 (0.61) | MMP2LMNAMC4RLOXL2 | |
| SCHEMBL6100385 | 0.82 | MMP2 (0.59) | MMP2LMNAKMT2AMC4RLOXL2 | |
| SCHEMBL5000615 | 0.82 | MMP2 (0.59) | MMP2LMNAKMT2AMC4RLOXL2 | |
| SCHEMBL6798022 | 0.80 | MMP2 (0.56) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL7065249 | 0.80 | MMP2 (0.56) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL7065251 | 0.80 | MMP2 (0.56) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL12793689 | 0.80 | MMP2 (0.57) | MMP2LMNAMC4RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397339-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-10-16 | — | — | US | disclosed |
| WO-2003000647-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | PGD, AADAT, TRHDE | MMP2 3977/4885LMNA 3353/4885MEN1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.